Enlivex Therapeutics Ltd
(ENLV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,218 | -31,060 | -23,871 | -18,138 | -8,225 |
| Depreciation Amortization | 209 | 777 | 556 | 364 | 188 |
| Accounts receivable | N/A | N/A | N/A | -211 | 1,058 |
| Accounts payable and accrued liabilities | -457 | 1,168 | 179 | N/A | 480 |
| Other Working Capital | -1,008 | 804 | -387 | -1,550 | 1,829 |
| Other Operating Activity | 2,690 | 4,358 | 4,388 | 6,993 | 1,401 |
| Operating Cash Flow | $-5,784 | $-23,953 | $-19,135 | $-12,542 | $-3,269 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -31,184 | 70,646 | 70,941 | 25,707 | 60,626 |
| PPE Investments | -162 | -8,122 | -5,541 | -4,351 | -952 |
| Investing Cash Flow | $-31,346 | $62,524 | $65,400 | $21,356 | $59,674 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 318 | 150 | 150 | 100 | 50 |
| Financing Cash Flow | $318 | $150 | $150 | $100 | $50 |
| Beginning Cash Position | 50,357 | 11,636 | 11,636 | 11,636 | 11,636 |
| End Cash Position | 13,545 | 50,357 | 58,051 | 20,550 | 68,091 |
| Net Cash Flow | $-36,812 | $38,721 | $46,415 | $8,914 | $56,455 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,784 | -23,953 | -19,135 | -12,542 | -3,269 |
| Capital Expenditure | -162 | -8,122 | -5,541 | -4,351 | -952 |
| Free Cash Flow | -5,946 | -32,075 | -24,676 | -16,893 | -4,221 |